Methods and compositions involving (S)-bucindolol
US9446023B2 · kind B2 · utility
4Cited by
12References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 6, 2015 |
| Grant date | Sep 20, 2016 |
| Priority date | — |
| Expiry date | Jan 6, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/204
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.